November 26, 2019 / 6:59 AM / 17 days ago

BRIEF-Pharma Mar Gets Orphan Drug Designation For Lurbinectedin By Swiss Agency For SCLC

Nov 26 (Reuters) - Pharma Mar SA:

* RECEIVES DESIGNATION OF ORPHAN DRUG FOR LURBINECTEDINA BY SWISS AGENCY OF THERAPEUTIC PRODUCTS FOR SMALL CELL LUNG CANCER (SCLC)

* DECISION IS BASED ON ORPHAN DRUG RECOGNITION GRANTED BY EUROPEAN MEDICINES AGENCY ON FEB. 26 Source text: bit.ly/33kaX43 Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below